Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cardiff Oncology Inc CRDF

Healthcare Biotechnology
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal... see more

Recent & Breaking News (NDAQ:CRDF)

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

GlobeNewswire 7 days ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

GlobeNewswire October 30, 2024

Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update

GlobeNewswire August 8, 2024

Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update

GlobeNewswire August 1, 2024

Cardiff Oncology to Present at the Jefferies Healthcare Conference

GlobeNewswire May 29, 2024

Cardiff Oncology to Present at Upcoming Investor Conferences in May

GlobeNewswire May 13, 2024

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

GlobeNewswire May 2, 2024

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

GlobeNewswire April 25, 2024

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

GlobeNewswire April 8, 2024

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

GlobeNewswire March 6, 2024

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

GlobeNewswire February 29, 2024

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

GlobeNewswire February 29, 2024

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

GlobeNewswire February 29, 2024

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

GlobeNewswire February 26, 2024

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

GlobeNewswire February 22, 2024

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

PR Newswire January 17, 2024

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

PR Newswire November 20, 2023

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

PR Newswire November 2, 2023

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

PR Newswire October 26, 2023

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

PR Newswire September 26, 2023